ArticleJNCI cancer spectrum2024

Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas.

Mengyang Di et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.